What Will Happen to Avenue Therapeutics, Inc. (ATXI) Next? The Stock Just Increased A Lot

March 14, 2018 - By Hazel Jackson

The stock of Avenue Therapeutics, Inc. (NASDAQ:ATXI) is a huge mover today! The stock increased 14.32% or $0.68 during the last trading session, reaching $5.43. About 95,235 shares traded or 227.38% up from the average. Avenue Therapeutics, Inc. (NASDAQ:ATXI) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 5 months positive chart setup for the $55.74M company. It was reported on Mar, 14 by Barchart.com. We have $5.65 PT which if reached, will make NASDAQ:ATXI worth $2.23M more.

More notable recent Avenue Therapeutics, Inc. (NASDAQ:ATXI) news were published by: Globenewswire.com which released: “Avenue Therapeutics Receives Notice of Allowance for a New Patent Application …” on May 19, 2017, also Globenewswire.com with their article: “Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO …” published on February 06, 2018, Globenewswire.com published: “Avenue Therapeutics Completes Initial Public Offering” on June 30, 2017. More interesting news about Avenue Therapeutics, Inc. (NASDAQ:ATXI) were released by: Globenewswire.com and their article: “Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial …” published on March 01, 2018 as well as Globenewswire.com‘s news article titled: “Avenue Therapeutics to Present at March Investor Conferences” with publication date: March 05, 2018.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. The company has market cap of $55.74 million. The Company’s product candidate is IV Tramadol for the treatment of post-operative pain. It currently has negative earnings. The firm was founded in 2015 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.